Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Clopidogrel Taw Pharma (previously Clopidogrel Mylan)“
Suchtreffer
Begriffe & Kennungen
Clopidogrel Taw Pharma (previously Clopidogrel Mylan)
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.1 Therapeutic indications · 1
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.3 Contraindications · 1
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.3 · • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. • Severe hepatic
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · A significantly reduced platelet inhibition has been shown in HIV patients treated with ritonavir-or cobicista
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet agg
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Boosted anti-retroviral therapy (ART): HIV patients treated with boosted anti-retroviral therapies (ART) are a
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy vo
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safe
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of th
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Inducers of CYP2C19 Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medici
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Inhibitors of CYP2C19 Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medi
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole.
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomepr
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and
Eintrag öffnen